SGAM
BPMC

Smith Group Asset Management’s Blueprint Medicines BPMC Stock Holding History

Smith Group Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-70
Closed -$7K – 287
2021
Q4 		$7K Hold
70
– – ﹤0.01% 329
2021
Q3 		$7K Hold
70
– – ﹤0.01% 329
2021
Q2 		$6K Hold
70
– – ﹤0.01% 336
2021
Q1 		$7K Sell
70
-1,790
-96% -$179K ﹤0.01% 289
2020
Q4 		$209K Hold
1,860
– – 0.01% 179
2020
Q3 		$172K Hold
1,860
– – 0.01% 176
2020
Q2 		$145K Sell
1,860
-30
-2% -$2.03K 0.01% 177
2020
Q1 		$111K Hold
1,890
– – 0.01% 204
2019
Q4 		$151K Hold
1,890
– – 0.01% 219
2019
Q3 		$139K Buy
1,890
+640
+51% +$55.3K ﹤0.01% 217
2019
Q2 		$118K Hold
1,250
– – ﹤0.01% 228
2019
Q1 		$100K Sell
1,250
-3,400
-73% -$251K ﹤0.01% 259
2018
Q4 		$251K Sell
4,650
-100
-2% -$6.08K 0.01% 225
2018
Q3 		$371K Buy
4,750
+100
+2% +$6.95K 0.01% 207
2018
Q2 		$295K Buy
4,650
+100
+2% +$7.96K 0.01% 221
2018
Q1 		$417K Sell
4,550
-3,700
-45% -$319K 0.01% 202
2017
Q4 		$622K Hold
8,250
– – 0.02% 194
2017
Q3 		$575K Buy
+8,250
New +$441K 0.02% 208

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Smith Group Asset Management's BPMC Position: Q1 2022 in Review

Smith Group Asset Management sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 70 shares — an estimated $7K sold.

Smith Group Asset Management first reported a position in BPMC in Q3 2017 and held it in 18 quarters. The position peaked at $622K in Q4 2017. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Smith Group Asset Management reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 70 Blueprint Medicines shares in Q1 2022, an estimated $7K.
  • Smith Group Asset Management first reported a position in Blueprint Medicines in Q3 2017 and held it in 18 quarters.
  • Smith Group Asset Management's Blueprint Medicines position peaked at $622K in Q4 2017.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.